Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.



  • What evidence supports the efficacy of dalbavancin for the treatment of ABSSSIs?
  • What treatment options are available for the reversal of novel oral anticoagulants?
  • What is the evidence for the safety and efficacy of tedizolid for the treatment of ABSSSIs?


  • What is the status of biosimilars in the United States?
  • Preexposure prophylaxis for HIV prevention: What are the new guidelines?
  • How should acute pain be managed in patients taking Suboxone?


  • What is the new evidence behind the effectiveness of β-blocker therapy for outcomes post-myocardial infarction?
  • What are the findings of the HEAT-PPCI trial?
  • What is the role of thrombolysis in submassive pulmonary embolism?


  • What evidence supports the use of extended or continuous infusions for carbapenem administration?
  • What evidence describes the effect of inhaled morphine for dyspnea or pain?
  • What is the new guidance regarding palivizumab (Synagis®) administration for respiratory syncytial virus?


  • What are the proposals of the new USP <800> chapter, ' Hazardous Drugs – Handling in Healthcare Settings ? '
  • How should beyond-use-dates for compounded preparations be determined?
  • Is intravenous ketamine useful for the treatment of major depressive disorder?


  • Can patients with recurrent C difficile infection be treated with a prepared fecal microbiota transplant product?
  • What data are available comparing liposomal bupivacaine to other agents?
  • What is the Target: Stroke initiative and its effect on stroke outcomes?


  • What are the recommendations regarding blood pressure management in patients with an acute ischemic stroke?
  • What evidence supports the efficacy of the new oral factor Xa inhibitor, edoxaban?
  • Does testosterone increase the risk of a cardiovascular event?


  • What is the effective dose and duration of oral ribavirin for immunocompromised adult patients with RSV infection?
  • Is there any information regarding reducing the adverse effects from acetylcysteine in acetaminophen overdose?
  • What are the current guidelines on treatment of hyponatremia with vasopressin antagonists?


  • Is there a benefit to using colloid solutions versus crystalloid solutions as fluid resuscitation for patients with hypovolemic shock?
  • What drug products may be used in patients with anemia or hemorrhage who are Jehovah’s Witnesses?
  • What data are available to direct the dosing weight used for daptomycin in obesity?


  • Are there benefits to using genotype-guided warfarin dosing for INR control?
  • Does perioperative use of selective serotonin reuptake inhibitors increase the risk of adverse outcomes?
  • What is the evidence for the use of albumin for treatment of intradialytic hypotension?


  • What are the key features of the new hypertension treatment guidelines?
  • How do the novel oral anticoagulants compare to low-molecular-weight heparin for prevention of venous thromboembolism in patients undergoing total hip or knee replacements?
  • Is there evidence to support the use of lidocaine to reduce pain associated with potassium infusions?


  • What is the latest evidence associating statin use with myopathy?
  • What are current best practices for prevention of central-line associated bloodstream infections?
  • What are the key features of the new cholesterol treatment guidelines?